These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 19309243)
1. Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease. Agarwal AK Expert Opin Drug Saf; 2009 Mar; 8(2):145-53. PubMed ID: 19309243 [TBL] [Abstract][Full Text] [Related]
2. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease. Silver MR; Agarwal A; Krause M; Lei L; Stehman-Breen C Am J Geriatr Pharmacother; 2008 Jun; 6(2):49-60. PubMed ID: 18675764 [TBL] [Abstract][Full Text] [Related]
3. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R; N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844 [TBL] [Abstract][Full Text] [Related]
4. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Wilhelm-Leen ER; Winkelmayer WC Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816 [TBL] [Abstract][Full Text] [Related]
5. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis. Roger SD; Kolmakova E; Fung M; Malecki R; Vinhas J; Dellanna F; Thomas M; Manamley N; Ferenczi S Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498 [TBL] [Abstract][Full Text] [Related]
6. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Scott SD Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586 [TBL] [Abstract][Full Text] [Related]
7. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study. Gobin J; Cernii A; McLean R; Finkelstein FO; Simon DB Clin Drug Investig; 2011; 31(2):113-20. PubMed ID: 21067252 [TBL] [Abstract][Full Text] [Related]
8. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator. Yoshida T; Hayashi M Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008 [TBL] [Abstract][Full Text] [Related]
9. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. Li WY; Chu TS; Huang JW; Wu MS; Wu KD J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153 [TBL] [Abstract][Full Text] [Related]
10. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. Macdougall IC; Provenzano R; Sharma A; Spinowitz BS; Schmidt RJ; Pergola PE; Zabaneh RI; Tong-Starksen S; Mayo MR; Tang H; Polu KR; Duliege AM; Fishbane S; N Engl J Med; 2013 Jan; 368(4):320-32. PubMed ID: 23343062 [TBL] [Abstract][Full Text] [Related]
11. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease. Warady BA; Barcia J; Benador N; Jankauskiene A; Olson K; Podracka L; Shavkin A; Srivaths P; Wong CJ; Petersen J Pediatr Nephrol; 2018 Jan; 33(1):125-137. PubMed ID: 28815341 [TBL] [Abstract][Full Text] [Related]
12. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease. Hudson JQ; Sameri RM Pharmacotherapy; 2002 Sep; 22(9 Pt 2):141S-149S. PubMed ID: 12222584 [TBL] [Abstract][Full Text] [Related]
13. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Suranyi MG; Lindberg JS; Navarro J; Elias C; Brenner RM; Walker R Am J Nephrol; 2003; 23(2):106-11. PubMed ID: 12481149 [TBL] [Abstract][Full Text] [Related]
14. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. Mann J; Kessler M; Villa G; Martinez-Castelao A; Feldt-Rasmussen B; Cruz J; Hörl WH; Mattin C; Praml C; Wilkie M Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738 [TBL] [Abstract][Full Text] [Related]
15. Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Campistol JM; Carreño A; Morales JM; Pallardó L; Franco A; Navarro D; Grinyó JM; Montenegro J; Sánchez Fructuoso AI; Romero R; Guirado L; Arias M; Transplantation; 2013 Jan; 95(2):e6-e10. PubMed ID: 23325012 [No Abstract] [Full Text] [Related]
16. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Warady BA; Arar MY; Lerner G; Nakanishi AM; Stehman-Breen C Pediatr Nephrol; 2006 Aug; 21(8):1144-52. PubMed ID: 16724235 [TBL] [Abstract][Full Text] [Related]
18. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease. Grabe DW Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995 [TBL] [Abstract][Full Text] [Related]
19. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232 [TBL] [Abstract][Full Text] [Related]
20. Comparison of darbepoetin alpha and recombinant human erythropoietin for treatment of anemia in pediatric chronic kidney disease: a non-inferiority trial from India. Mazahir R; Anand K; Pruthi PK Eur J Pediatr; 2023 Jan; 182(1):101-109. PubMed ID: 36220980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]